ProBioGen AG is delighted to announce the signing of a service agreement for Nobelpharma’s highly relevant vaccine project.
Earlier work confirmed already the versatility and benefit of ProBioGen’s vaccine development platform, consisting of the proprietary, well-proven AGE1.CR.pIX® suspension cell line and its high performance cell culture medium, for the propagation of Nobelpharma’s virus strain.
Now, ProBioGen applies state-of-the-art technologies and a deep expertise to perform the upstream and downstream process development for Nobelpharma's highly relevant vaccine for large scale manufacturing.
The duck cell line AGE1.CR.pIX was designed to serve the industrial, GMP-compliant production of a wide variety of viruses in large bioreactors and is free of any adventitious agents.
It has already proven its great utility for viral vector production in various clinical trials.
ProBioGen is a Contract Development and Manufacturing Organization (CDMO) and technology provider with extensive expertise in cell line engineering, process development and GMP manufacturing of biopharmaceuticals.
Our proprietary technologies like CHO.RiGHT®, the genetic glyco-engineering GlymaxX® and the targeted transposase DirectedLuck™ in combination with our efficient process development and robust GMP manufacturing accelerate and advance the development of drug candidates – from early concept to industrial market-readiness.
ProBioGen provides modern manufacturing solutions for viral vectors with its continuous AGE1.CR® duck cell line, a vaccine platform with MVA-CR19 and renders technology support in gene therapy and vaccine development.
All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen is successfully serving international clients for more than 26 years, is privately owned and based in Berlin.